Taking into account the current epidemiological situation, "which continues to record a high circulation of the Sars-CoV-2 virus" and "in compliance with the principle of maximum precaution, to subjects with marked impairment of the immune response," the administration of a dose of mRNA vaccine, as a booster of a three-dose primary vaccination course (standard primary course plus additional dose) "provided that" a minimum interval of at least 120 days has elapsed from the additional dose ". Thus the signed circular by the Dg Prevention of the Ministry of Health, Gianni Rezza regarding the '4th' dose.
Taking into account the current epidemiological situation, "which continues to record a high circulation of the Sars-CoV-2 virus" and "in compliance with the principle of maximum precaution, to subjects with marked impairment of the immune response," the administration of a dose of mRNA vaccine, as a booster of a three-dose primary vaccination course (standard primary course plus additional dose) "provided that" a minimum interval of at least 120 days has elapsed from the additional dose ". Thus the signed circular by the Dg Prevention of the Ministry of Health, Gianni Rezza regarding the '4th' dose.
The circular on the recall for subjects with marked impairment of the immune response, for causes related to the underlying pathology or pharmacological treatments and to subjects undergoing solid organ transplantation, given the opinion of the CTS of Aifa of 18 February, specifies methods, dosages and timing of administration.
In particular: "A dose of mRNA vaccine, as a booster of a primary vaccination cycle divided into three doses (standard primary cycle plus additional dose at least 28 days after the last dose), in the dosages authorized for the purpose ( 30 mcg in 0.3 mL for Comirnaty in subjects 12 years of age and older; 50 mcg in 0.25 mL for Spikevax in subjects 18 years of age and older), provided that a minimum interval of at least 120 has elapsed days from the additional dose "
"Considering - reads the circular - the current evidence that in the face of a reduction in the protective effect and duration of immunization after the primary vaccination cycle against the Omicron variant, however, reveal high levels of efficacy and safety of the booster dose in preventing forms symptoms, hospital admissions and deaths related to Covid-19 ".
